ABOUT THE PRODUCT
EZMEKLY® (mirdametinib) is a targeted therapy approved for the treatment of adult and pediatric patients with NF1-PN.
Information is owner-confirmed
Last updated 2 weeks ago
Price range
Other products/services from SpringWorks Therapeutics
OGSIVEO® (nirogacestat)
Biotechnology
N/A
SpringWorks Therapeutics
United States (US)